Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Passage Bio, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
PASG
Nasdaq
2830
www.passagebio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Passage Bio, Inc.
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Jan 10th, 2025 12:00 pm
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
- Dec 29th, 2024 12:20 pm
Passage Bio assumed with an Outperform at Wedbush
- Nov 30th, 2024 11:55 am
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
- Nov 29th, 2024 2:00 pm
Passage Bio Achieves Milestones in Gene Therapy Trials
- Nov 14th, 2024 12:29 pm
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Nov 13th, 2024 12:00 pm
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
- Nov 6th, 2024 12:00 pm
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
- Oct 24th, 2024 11:00 am
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
- Sep 24th, 2024 1:36 am
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
- Sep 23rd, 2024 11:00 am
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
- Sep 19th, 2024 5:25 am
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
- Sep 16th, 2024 11:00 am
Passage Bio Welcomes Tom Kassberg to Board of Directors
- Sep 10th, 2024 11:52 am
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Aug 30th, 2024 11:00 am
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
- Aug 8th, 2024 11:00 am
Passage Bio to Participate in Upcoming Investor Conferences
- Aug 6th, 2024 11:00 am
Jim Wilson, prominent gene therapy researcher, to depart UPenn
- Aug 1st, 2024 4:30 pm
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
- Aug 1st, 2024 11:00 am
Passage Bio targets FDA to greenlight ALS gene therapy trial
- Jul 25th, 2024 11:13 am
Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?
- Jul 21st, 2024 2:20 pm
Scroll